NAMD Submits Comments on Medicaid Drug Rebate Program Proposed Rule
On July 25, NAMD submitted comments on CMS's proposed rule on the Medicaid Drug Rebate Program (MDRP).
Letter ·
NAMD Comments on Senate Finance Committee’s Generic Drug Legislation
The legislation would exclude most generic drugs from the Medicaid Drug Rebate Program’s inflationary rebates.
On June 7, NAMD submitted comments on the Senate Finance Committee’s draft legislation on generic drug shortages. In our comments, we highlight concerns that the legislation, as written, would weaken the Medicaid Drug Rebate Program and fail to address the root causes of generic drug shortages.
Related resources
Prescription Drug Spending: What’s Coming Next for Medicaid and How Can States Prepare?
Experts at the NAMD Fall Conference discussed challenges with high-cost drugs.
NAMD Comments on Medicare’s Proposed Coverage Determination for Alzheimer’s Drug
On February 9, 2022, NAMD submitted comments on Medicare’s proposed National Coverage Determination (NCD) of Coverage with Evidence...
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.